Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17577020 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)(COMPLETED)
Conditions: Cutaneous T-cell Lymphoma;   Sezary Syndrome;   Mycosis Fungoides
Intervention: Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

Indicates status has not been verified in more than two years